We empower people with innovative treatment solutions

 

News & Insights

JULY 10, 2024
Orexo AB´s sustainability work ranked among top 5% by EcoVadis

JULY 8, 2024
Invitation to presentation of the Q2 Interim Report on July 17 at 2 pm CET

JULY 4, 2024
Meet our people: Orexo's scientist Jonas Sävmarker on being curious and innovating for patients 

 

 

A commercial stage pharmaceutical company with three revenue generating pharmaceutical products

 


AmorphOX® - a world-class powder-based drug delivery technology, leading to a new wave of a both small and large molecule pharmaceuticals.

 

 

Development pipeline targeting large medical needs

ESG sustainable investing

Read all documents related to the refinancing of the existing bond - MARCH 2024

Read more

Key financial figures

Group net revenue

619 MSEK
Last Twelve Months, Q223-Q124

Group EBITDA

24 MSEK
Last Twelve Months, Q223-Q124

US Commercial segment EBIT

146 MSEK
Last Twelve Months, Q223-Q124

Cash position

198 MSEK
Q124

News Flow

Regulatory Press Releases

To read all NEWS go to Media in the top menu